AJR Am J Roentgenol
- TAILOR TD, Christensen JD
Beyond the AJR: Potential Role for Opportunistic Lung Cancer Screening.
AJR Am J Roentgenol. 2024 Mar 13. doi: 10.2214/AJR.24.31039.
Am J Ind Med
- ALEXANDER BH, Ryan A, Church TR, Kim H, et al
Mortality and cancer incidence in perfluorooctanesulfonyl fluoride production
workers.
Am J Ind Med. 2024;67:321-333.
Ann Surg Oncol
- PARK S, Choe J, Lee SM, Choi S, et al
ASO Visual Abstract: Surgical Outcomes in Non-small Cell Lung Cancer with Distant
Metastasis: The Prognostic Significance of Delayed Metastasis Diagnosis.
Ann Surg Oncol. 2024 Mar 14. doi: 10.1245/s10434-024-15135.
Arch Bronconeumol
- SARDELLA L, Merlo E, Casutt A
Endobronchial High-Grade Non-Hodgkin B-Cell Lymphoma Mimicking Small Cell Lung
Cancer.
Arch Bronconeumol. 2024 Feb 24:S0300-2896(24)00052.
BMC Cancer
- KAHM YJ, Kim IG, Kim RK
Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is
controlled by MCM2.
BMC Cancer. 2024;24:319.
- WANG S, Oliveira-Silveira J, Fang G, Kang J, et al
High-content analysis identified synergistic drug interactions between INK128, an
mTOR inhibitor, and HDAC inhibitors in a non-small cell lung cancer cell line.
BMC Cancer. 2024;24:335.
- PAN J, Wang J, Tao W, Wang C, et al
Is low-dose computed tomography for lung cancer screening conveniently accessible
in China? A spatial analysis based on cross-sectional survey.
BMC Cancer. 2024;24:342.
Cancer
- CITTOLIN-SANTOS GF, Knapp B, Ganesh B, Gao F, et al
The changing landscape of small cell lung cancer.
Cancer. 2024 Mar 12. doi: 10.1002/cncr.35281.
Cancer Cell
- HU F, Lito P
Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
Cancer Cell. 2024;42:330-332.
- HE XY, Gao Y, Ng D, Michalopoulou E, et al
Chronic stress increases metastasis via neutrophil-mediated changes to the
microenvironment.
Cancer Cell. 2024;42:474-486.
Carcinogenesis
- VISONA SD, Bertoglio B, Capella S, Belluso E, et al
Asbestos burden in lungs of mesothelioma patients with pleural plaques, lung
fibrosis and/or ferruginous bodies at histology: a postmortem SEM-EDS study.
Carcinogenesis. 2024;45:131-139.
Chest
- OST DE
Development and Revision of Meaningful Stage Descriptors for M1a Non-Small Cell
Lung Cancer.
Chest. 2024;165:490-491.
- MELZER AC, Begnaud A
Planting the Seeds for Lung Cancer Screening Starts With Knowledge Holders.
Chest. 2024;165:488-489.
- CHRISTENSEN J, Prosper AE, Wu CC, Chung J, et al
ACR Lung-RADS v2022: Assessment Categories and Management Recommendations.
Chest. 2024;165:738-753.
- LIAO Z, Wang H, An J, Dong J, et al
A 49-Year-Old Man With Fever and Dyspnea After Endobronchial Ultrasound-Guided
Transbronchial Fine Needle Aspiration Biopsy.
Chest. 2024;165:e65-e69.
Clin Exp Metastasis
- OKUNO T, Isobe T, Tsubata Y
Current pharmacologic treatment of brain metastasis in non-small cell lung
cancer.
Clin Exp Metastasis. 2024 Mar 11. doi: 10.1007/s10585-024-10276.
Clin Lung Cancer
- D'AIELLO A, Stiles B, Ohri N, Levy B, et al
Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application
of Emerging Data and New Challenges.
Clin Lung Cancer. 2024 Feb 13:S1525-7304(24)00015.
Eur J Cancer
- KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
Impact of central nervous system metastasis after complete resection of lung
adenocarcinomas harboring common EGFR mutation - A real-world database study in
Japan: The CReGYT-01 EGFR study.
Eur J Cancer. 2024;201:113951.
Eur J Cardiothorac Surg
- MIURA K, Ide S, Minamisawa M, Mishima S, et al
Sublobar resection or lobectomy and postoperative respiratory complications in
emphysematous lungs.
Eur J Cardiothorac Surg. 2024;65:ezae061.
Int J Cancer
- KOURO T, Higashijima N, Horaguchi S, Mano Y, et al
Novel chimeric antigen receptor-expressing T cells targeting the malignant
mesothelioma-specific antigen sialylated HEG1.
Int J Cancer. 2024;154:1828-1841.
J Cancer Res Clin Oncol
- SHIJUBOU N, Sumi T, Kubo T, Sasaki K, et al
Prognostic significance of immunohistochemical classification utilizing biopsy
specimens in patients with extensive-disease small-cell lung cancer treated with
first-line chemotherapy and immune checkpoint inhibitors.
J Cancer Res Clin Oncol. 2024;150:125.
- JU W, Lin L, Zhang Q, Lv X, et al
GATA6 inhibits the biological function of non-small cell lung cancer by
modulating glucose metabolism.
J Cancer Res Clin Oncol. 2024;150:126.
J Clin Oncol
- RODRIGUEZ GM, Popat R, Rosas LG, Patel MI, et al
Racial and Ethnic Disparities in Intensity of Care at the End of Life for
Patients With Lung Cancer: A 13-Year Population-Based Study.
J Clin Oncol. 2024 Mar 13:JCO2301045. doi: 10.1200/JCO.23.01045.
J Natl Cancer Inst
- NAGASAKI Y, Taki T, Nomura K, Tane K, et al
Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts
poor prognosis in resected non-small cell lung cancer.
J Natl Cancer Inst. 2024 Mar 8:djae053. doi: 10.1093.
J Nucl Med
- THOR M, Lee C, Sun L, Patel P, et al
An (18)F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation
Pneumonitis in Stage III Non-Small Cell Lung Cancer Patients Treated with
Chemoradiation and Immunotherapy.
J Nucl Med. 2024 Mar 14:jnumed.123.266965. doi: 10.2967/jnumed.123.266965.
J Thorac Cardiovasc Surg
- KIM AT, Ding L, Lee HB, Ashbrook MJ, et al
Longer hospitalizations, more complications, and greater readmissions for
patients with comorbid psychiatric disorders undergoing pulmonary lobectomy.
J Thorac Cardiovasc Surg. 2024;167:1502-1511.
- ODEH AM, Perez-Tamayo RA, Abdelsattar ZM
A wedge is still better than stereotactic body radiation therapy in the national
cancer database.
J Thorac Cardiovasc Surg. 2024;167:e100-e101.
J Thorac Oncol
- YANG SR, Gedvilaite E, Ptashkin R, Chang J, et al
Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct
Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational
Burden, and Recurrent Somatic MLH1 Inactivation.
J Thorac Oncol. 2024;19:409-424.
- BORCZUK AC
Invasive Size in Lung Adenocarcinoma-Reproducible Criteria, More Accurate
Staging.
J Thorac Oncol. 2024;19:360-362.
- CANI M, Novello S, Bironzo P
Mismatch Repair Deficiency in Lung Tumors: Adding a New Layer of Complexity on
Pie Slices.
J Thorac Oncol. 2024;19:363-365.
- DAMMEIJER F, Dumoulin DW, Aerts JGJV
Anti-Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1
Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary.
J Thorac Oncol. 2024;19:366-369.
- YALAMANCHALI A, Hassan KA
MUC1-C: The Occam Razor of Osimertinib Resistance?
J Thorac Oncol. 2024;19:370-372.
- LIM SM, Lee JB, Cho BC
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment
for All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:376-379.
- CHEN LN, Lee ATM, Nagasaka M, Ou SI, et al
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for
All Advanced EGFR+ NSCLC.
J Thorac Oncol. 2024;19:380-384.
- LI CP, Tsai RY, Chang HC, Gau SY, et al
Survival and Prognosis After Carbon-Ion Radiotherapy in Patients With NSCLC.
J Thorac Oncol. 2024;19:507-508.
- CHENG Y, Fan Y, Zhao Y, Huang D, et al
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and
Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
(RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized,
Phase 3 Clinical Trial
J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115.
- HINES JB, Cameron RB, Esposito A, Kim L, et al
Evaluation of MPR and pCR as surrogate endpoints for survival in randomized
controlled trials of neoadjuvant immune checkpoint blockade in resectable in
non-small cell lung cancer.
J Thorac Oncol. 2024 Mar 8:S1556-0864(24)00117.
Lancet Oncol
- GOULART BHL, Mushti SL, Chatterjee S, Larkins E, et al
Correlations of response rate and progression-free survival with overall survival
in immunotherapy trials for metastatic non-small-cell lung cancer: an FDA pooled
analysis.
Lancet Oncol. 2024 Mar 5:S1470-2045(24)00040.
Lung Cancer
- KIM DW, Chul Cho B, Pachipala K, Kim SW, et al
Durvalumab in combination with chemoradiotherapy for patients with unresectable
stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Lung Cancer. 2024;190:107530.
Oncogene
- KUMAR V, Yochum ZA, Devadassan P, Huang EH, et al
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for
MET driven acquired resistance in oncogene driven lung cancer.
Oncogene. 2024 Mar 1. doi: 10.1038/s41388-024-02987.
PLoS One
- AHMAD A, Kulachi MO, Farman M, Junjua MU, et al
Mathematical modeling and control of lung cancer with IL2 cytokine and anti-PD-L1
inhibitor effects for low immune individuals.
PLoS One. 2024;19:e0299560.
- LEE YJ, Kang N, Nam J, Lee EG, et al
The preventative effects of statin on lung cancer development in patients with
idiopathic pulmonary fibrosis using the National Health Insurance Service
Database in Korea.
PLoS One. 2024;19:e0299484.
- MALIK H, Anees T
Multi-modal deep learning methods for classification of chest diseases using
different medical imaging and cough sounds.
PLoS One. 2024;19:e0296352.
- XUE Y, Zhang D, Jia L, Yang W, et al
Integrating image and gene-data with a semi-supervised attention model for
prediction of KRAS gene mutation status in non-small cell lung cancer.
PLoS One. 2024;19:e0297331.
- MAJUMDER S, Gautam N, Basu A, Sau A, et al
MENet: A Mitscherlich function based ensemble of CNN models to classify lung
cancer using CT scans.
PLoS One. 2024;19:e0298527.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016